Neutralizing antibodies in hepatitis C virus infection

Table 1 HCV epitopes targeted by antibodies interfering with cellular HCV envelope glycoprotein binding, viral entry or infection

Envelopeglycoprotein	Epitope(Amino acids)	Potential function	Model system
E1
	192-226		HCV-LP binding[85]
	197-207		HCV-LP binding[24]
	270-284	Membrane fusion	HCVpp entry[63]
	313-332		HCV-LP binding[85]
E2
	HVR-1	SR-BI/heparan sulfate binding	Chimpanzee[38]
	HVR-1	SR-BI/heparan sulfate binding	E2 binding, HCVpp entry[18,27]
	396-407		HCVpp entry[12]
	408-422		HCV-LP binding[22]
	412-419		HCVpp entry[55]
	412-423		HCVpp entry, HCVcc infection[12,57]
	416-430	Membrane fusion	HCVpp entry[63]
	432-443		HCVpp entry[12]
	436-447		HCVpp entry[12]
	474-494	CD81 binding	E2 binding, HCVpp entry[56,86]
	522-551	CD81 binding	E2 binding, HCVpp entry[56,86]
	600-620	Membrane fusion	HCVpp entry[63]
	640-653		HCV-LP binding[24]
	644-655		HCVpp entry[12]
	CD		E2 binding, HCVpp entry[58-61]

Envelope glycoprotein epitope (position amino acid within the HCV polyprotein) and its potential function with the viral entry process is shown. The experimental system for antibody-mediated inhibition of viral binding, entry or infection is listed together with the respective reference. CD: Conformation-dependent; E1 and E2: Envelope glycoproteins E1 and E2; HCV-LP: HCV-like particles; HVR-1: Hypervariable region-1; HCVpp: HCV pseudotyped particles; HCVcc: Cell-culture derived HCV; SR-BI: Scavenger receptor class B typeI.